MedTrace Logo

Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

NCT07465198 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-11

No results posted yet for this study

Summary

This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.

Conditions

  • MSA - Multiple System Atrophy
  • MSA

Interventions

DRUG

MSCs

IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period

OTHER

Placebo

Intravenous 0.9% saline infusion, volume- and appearance-matched

Sponsors & Collaborators

  • Biocells Medical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2029-09-01
Completion
2031-03-01

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07465198 on ClinicalTrials.gov